Výsledky vyhledávání - "Serum infliximab"

Akademický článek

Serum infliximab levels and clinical response in hidradenitis suppurativa

Autor: Erwin Benassaia, Jean‐David Bouaziz, Marie Jachiet, Florence Cordoliani, Anne Saussine, Clemence Lepelletier, Lauriane Goldwirt, Charles Cassius, Adèle deMasson, Martine Bagot, Hervé Bachelez, Florence Assan

Publikováno v: JEADV Clinical Practice, Vol 2, Iss 2, Pp 306-312 (2023)

Abstract Background Infliximab (IFX) is a chimeric immunoglobulin G‐1κ monoclonal antibody that neutralises the biologic activity of tumour necrosis factor‐α, and has shown efficacy (off‐label) for the treatment of severe hidradenitis suppura

Externí odkaz: https://doaj.org/article/5023272012534ed2bade94e57763d475

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier

Autor: Nastya Kharlamova, Christina Hermanrud, Nicky Dunn, Malin Ryner, Karen Hambardzumyan, Nancy Vivar Pomiano, Per Marits, Inger Gjertsson, Saedis Saevarsdottir, Rille Pullerits, Anna Fogdell-Hahn

Publikováno v: Frontiers in Immunology, Vol 11 (2020)

A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to a more personalized and efficient tr

Externí odkaz: https://doaj.org/article/79dbf46073304c1b828a8088bc48196f

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

Autor: Charlotte Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John D Isaacs, Astrid van Tubergen

Publikováno v: Krieckaert, CLM, Hernandez-Breijo, B, Gehin, JE, le Mélédo, G, Balsa, A, Jani, M, Mulleman, D, Navarro-Compán, V, Wolbink, G J, Isaacs, J D & van Tubergen, A 2022, ' Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider ', RMD Open . https://doi.org/10.1136/rmdopen-2022-002216
Krieckaert, C, Hernández-Breijo, B, Gehin, J E, le Mélédo, G, Balsa, A, Jani, M, Mulleman, D, Navarro-Compan, V, Wolbink, G, Isaac, J & van Tubergen, A 2022, ' Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease : A systematic literature review informing EULAR points to consider ', RMD Open, vol. 8, no. 2, e002216 . https://doi.org/10.1136/rmdopen-2022-002216

The objectives of this review were to collect and summarise evidence on therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases and to inform the EULAR Task Force for the formulation of evidence-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f7010479860793811264f765020f4dc
https://www.research.manchester.ac.uk/portal/en/publications/therapeutic-drug-monitoring-of-biopharmaceuticals-in-inflammatory-rheumatic-and-musculoskeletal-disease-a-systematic-literature-review-informing-eular-points-to-consider(4c933746-dbae-417c-b199-adc9d36a51c7).html